A Phase II Study Of Allogeneic Transplant For Older Patients With AML In First Morphologic Complete Remission Using A Non-Myeloablative Preparative Regimen.
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Antithymocyte globulin; Busulfan; Filgrastim; Fludarabine; Methotrexate; Tacrolimus; Tacrolimus
- Indications Acute myeloid leukaemia; Graft-versus-host disease
- Focus Therapeutic Use
- 12 Jun 2018 Biomarkers information updated
- 06 Sep 2012 Planned End Date changed from 1 Apr 2005 to 1 Jan 2014 as reported by ClinicalTrials.gov.
- 06 Sep 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.